Familial British Dementia (FBD) is the early-onset autosomal dominant disorders characterized by cognitive impairment. The ABri is a 34-mer peptide which is the main component of amyloid deposits in FBD. As a first step toward shedding light for the discovery of amyloid inhibition drugs for FBD, we set the optimal conditions for quantification ABri peptide by the fluorescamine and alpha imager assay, which can provide a precise peptide quantity for determination of amyloid inhibition rate at micromolecular level and estimate aggregation rate by measuring monomer and dimer quantity which are filtered through 10,000 Da MW cutoff filter